Decision to list medical devices supplied by Medartis New Zealand Ltd and Pioneer Medical Limited
7 June 2019
What we’re doing
We are pleased to announce the approval of non-exclusive listing agreements with Medartis New Zealand (“Medartis”) and Pioneer Medical Limited (“Pioneer”) for the supply of orthopaedic implants and associated products (“Orthopaedic Products”) to DHBs.
In summary, this will result in the following ranges being listed in Part III of Section H of the Pharmaceutical Schedule from 1 July 2019:
- Medartis’ range of trauma and distal joint implants
- Pioneer’s range of spine, hip and knee implants
DHBs will be able to continue to purchase other suppliers’ brands of Orthopaedic Products as the agreements are not for sole supply.
Any changes to the original proposal?
This decision was subject to a consultation letter dated 7 May 2019.
No changes have been made to the Medartis agreement.
The Pioneer agreement has been amended to include an additional pricing option and this will be notified to appropriate DHB procurement personnel.
Who we think will be most interested
- Suppliers and Wholesalers
- DHB Staff:
- Orthopaedic surgeons
- Perioperative personnel
- Sterile services personnel
- Procurement and supply chain personnel
Detail about this decision
In April 2016 PHARMAC issued a request for proposals (“RFP”) for orthopaedic implants and associated products. The RFP requested proposals for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
After evaluating Medartis’ and Pioneer’s proposals and consulting on the provisional agreements reached with them, PHARMAC has decided to list Medartis’ and Pioneer’s ranges of Orthopaedic Products in Part III of Section H of the Pharmaceutical Schedule from 1 July 2019.
The following product ranges and brands are included in the agreements:
Trauma and distal joint implants
Our response to what you told us
We appreciate the time people took to respond to this consultation.
All consultation responses received by 28 May 2019 were considered in their entirety in making the decision to approve each agreement.
A summary of the only theme raised in feedback and our response to the feedback received is set out below:
|Medartis and Pioneer|
|No technical or resource impacts anticipated||Noted|
If you have any questions about this decision, you can email us at email@example.com; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.
Last updated: 7 June 2019